Transventricular non-transmural laser treatment of hypoperfused porcine myocardium acutely reduces left ventricular contractile function

Kanellopoulos, Georgios K.; Svindland, Aud; Ilebekk, Arnfinn; Goverud, Ingeborg Løstegaard; Kvernebo, Knut

doi:10.1016/s1010-7940(99)00169-4

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main contraindications are patients with unstable angina pectoris and cardiac insufficiency (left ventricular ejection fraction under 35%) because of high perioperative mortality and morbidity [29,41,[46][47][48].…”

Section: Practical Laser Applicationmentioning

confidence: 99%

Transmyocardial Laser Revascularization: Established Procedure, Acupuncture of the Heart or Placebo Effect?

Eckstein¹,

Boss²,

Frenz

et al. 2001

Heart Drug

View full text Add to dashboard Cite

Considering the nearly universal skepticism transmyocardial laser revascularization (TMLR) aroused a few years ago, the so-called snake heart procedure has come a long way. The notion that the human heart enjoys significant perfusion from a spongy underlay of microcapillaries and sinusoids has been embraced by hundreds of researchers who have poked away at the coronary bed with external and internal lasers, radiofrequency probes, rotary cutters and saline jets, as well as developing technologies for implanting angiogenic growth factors into and around the resultant channels. TMLR has been described as a therapeutic option for end-stage coronary artery disease when percutaneous transluminal angioplasty and surgical myocardial revascularization are no longer possible and transplantation is not indicated. While debate continues to rage among surgeons and interventionists over the best way to perform transmyocardial laser, a greater question looms over the field: how does it work? No one has been able to explain yet why the procedure works in some patients and utterly fails in others, or to convincingly substantiate the procedure’s contributions to myocardial reperfusion. A few investigators believe that the procedure’s secret lies in creating patent channels. However, mid- and long-term patency of laser-created channels seem not to be required for successful treatment as initially assumed. The development of new vessels within and around the scar following TMLR (a phenomenon called ‘neoangiogenesis’) has moved more and more to the center of attention during the last few years. Some form of angiogenesis or neovascularization around the channels is the most favored explanation now, but nobody knows how TMLR stimulates such processes or how to measure them effectively. Although prospective randomized studies have been able to demonstrate some effectiveness of this treatment, the exact mechanisms of laser revascularization are still not completely elucidated. The notion of mechanisms such as sympathetic myocardial denervation and induction of microinfarctions transforming ischemia into necrotic myocardium has been abandoned. As recently as 1996, the prospect of transmyocardial revascularization becoming a breakthrough therapy seemed exciting enough to the financial market that the stock of PLC Medical Systems, then the front-runner in the field, soared to USD 32 per share. But in only the 2nd year since receiving FDA approval, the company is now trading at around USD 1.5 a share and the laser sales have fallen below expectations. One problem may be that many hospitals do not switch on their TMLR lasers very often once they are installed, with usage estimates as low as one or two procedures per month in some centers.

show abstract

Section: Practical Laser Applicationmentioning

confidence: 99%